The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to β-lactams in a large teaching hospital

Pharmacotherapy

Volumn 23, Issue 5, 2003, Pages 618-624

  Regal, Randolph E ^a   DePestel, Daryl D ^a   VandenBussche, Heather L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG PREFERENCE; DRUG USE; DRUG UTILIZATION; GRAM NEGATIVE INFECTION; HUMAN; INFECTION CONTROL; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; PSEUDOMONAS AERUGINOSA; TEACHING HOSPITAL;

ANTI-BACTERIAL AGENTS; CEFTAZIDIME; DATA COLLECTION; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; HOSPITAL BED CAPACITY, 500 AND OVER; HOSPITALS, TEACHING; HUMANS; MICROBIAL SENSITIVITY TESTS; PRACTICE GUIDELINES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 0038708419     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.5.618.32197     Document Type: Article

References (25)

1. Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia: Churchill-Livingstone, 2000:2310-35.
2. Dancer SJ. The problem with cephalosporins. J Antimicrob Chemother 2001;48:463-78.
3. Sanders WE Jr, Sanders CC. Inducible β-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev infect Dis 1988;10:830-8.
4. Carsenti-Etesse H, Cavallo JD, Roger PM, et al. Effect of β-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 2001;7:144-51.
5. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996;23:118-24.
6. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999;28:1062-6.
7. Postelnick MJ, Peterson, LR, Noskin, GA. Effect of changes in antimicrobial agent use on bacterial pathogens recovered from hospitalized patients: a 6-year assessment. J Clin Outcomes Manage 1998;5:21-32.
8. Smith DW. Decreased antimicrobial resistance after changes in antibiotic use. Pharmacotherapy 1999;19(8 pt 2):129S-32, 133S-7.
9. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;2:1020-5.
10. Anonymous. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995;44(RR-12):1-13.
11. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standards. Document M7-A5, vol. 20, no. 2. Wayne, PA: NCCLS, 2000.
12. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 7th ed. Approved standards. Document M2-A7, vol. 20, no. 1. Wayne, PA: NCCLS, 2000.
13. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 12th informational supplement. M100-S12, vol. 22, no. 1. Wayne, PA: NCCLS, 2002.
14. Grimm H. Parallel resistance between cephalosporins and penicillins. Arzneimittelforschung 1984;34:62-5.
15. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233-7.
16. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000;21:455-8.
17. Empey KM, Rapp RP, Evans ME. The effect of an antimicrobial formulary change on hospital resistance patterns. Pharmacotherapy 2002;22:81-7.
18. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990;34:2193-9.
19. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-8.
20. Bradley SJ, Wilson AL, Allen MC, Sher HA, Goldstone AH, Scott GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43:261-6.
21. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634-40.
22. Lister PD. β-Lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against Enterobacteriaceae and Pseudomonas aeruginosa. Pharmacotherapy 2000;20(9 pt 2):213S-18.
23. Weingarten CM, Rybak MJ, Jahns BE, Stevenson JG, Brown WJ, Levine DP. Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital. Pharmacotherapy 1999;19:1080-5.
24. Schentag JJ. The results of a targeted pharmacy intervention program. Clin Ther 1993;15(suppl A):29-36.
25. Burke JP. Antibiotic resistance - squeezing the balloon [letter]? JAMA 1998;280:1270-1.